Higher levels of ambient nitrogen dioxide may be linked to an increased incidence of ovarian cancer, while associations with other pollutants remain inconclusive.
Greater levels of ambient nitrogen dioxide (NO2) exposure may be associated with higher ovarian cancer incidence, according to a research letter published in Environmental Health Perspectives.1
The researchers noted that outdoor air pollution is classified as a group 1 carcinogen, primarily due to associations with lung cancer.2 However, it has increasingly been associated with a higher incidence of other cancers, like uterine and breast cancers.1 Ovarian cancer shares a hormonal etiology with breast and uterine cancers, so they considered its association with outdoor air pollution.
Many past studies that evaluated the relationship between outdoor air pollution and ovarian cancer analyzed mortality rather than incidence. However, one recent study found a positive association between county-level estimates of ambient particulate matter (PM2.5) and ovarian cancer incidence.3 Building upon this literature, the researchers investigated the association between individual-level residential estimates of air pollution (NO2, PM2.5, and ozone [O3]) and incident ovarian cancer.1
Higher levels of ambient nitrogen dioxide may be linked to an increased incidence of ovarian cancer. | Image Credit: hramovnick - stock.adobe.com
To do so, they analyzed patients from the Sister Study (2003-2009), which enrolled 50,884 women across the US between the ages of 35 and 74 years with at least 1 sister who had breast cancer but no prior breast cancer themselves. However, they excluded those who withdrew, had missing data, or had a history of ovarian cancer or bilateral oophorectomy at baseline; this resulted in 40,308 eligible women.
Among the study population, ovarian cancer diagnoses were self-reported during annual follow-up surveys and confirmed using medical records when available. Also, the researchers estimated 12-month average ambient concentrations of NO2, PM2.5, and O3 over the follow-up period at the participants’ primary residential addresses.
Then, they used Cox proportional hazards models to estimate HRs for ovarian cancer based on increased pollutant levels, adjusting for various risk factors, including race/ethnicity, neighborhood socioeconomic status, and reproductive history. Additionally, the study explored how menopausal status, US Census region, and residential urbanicity influenced this relationship.
During the mean (standard deviation [SD]) follow-up time of 9.8 (2.5) years, 249 of the 40,308 participants were diagnosed with ovarian cancer. According to the US Census, 31.3% (n = 78) lived in the South, 29.3% (n = 73) in the Midwest, 23.7% (n = 59) in the West, and 15.7% (n = 39) in the Northeast.
The researchers found that a 5 parts per billion (ppb) increase in NO2 was associated with a higher incidence of ovarian cancer (HR, 1.21; 95% CI, 1.04-1.41). This association remained consistent after adjusting for co-pollutants (HR, 1.21; 95% CI, 0.99-1.47) and ovarian cancer risk factors (HR, 1.17; 95% CI, 0.95-1.43).
Conversely, after adjusting for co-pollutants, PM2.5 was not linked to ovarian cancer (HR, 1.02; 95% CI, 0.65-1.60). However, there were elevated but imprecise estimates among premenopausal women (HR, 2.85; 95% CI, 0.98-8.29) and those living in either the Midwest (HR, 1.40; 95% CI, 0.40-4.89) or West (HR, 1.63; 95% CI, 0.75-3.52).
Similarly, a heightened association between ovarian cancer and O3 exposure was discovered during premenopausal years (HR, 1.36; 95% CI, 0.88-2.10), but no association was observed otherwise.
The researchers acknowledged their study’s limitations, including that it had limited power to explore ovarian cancer histotypes or relevant subgroups. Also, the exposure estimates do not capture air pollution indoors or away from the home. Despite their limitations, they suggested areas for future research based on their findings.
“Given the rarity of ovarian cancer, studies that pool data from multiple prospective cohorts are needed to examine associations by tumor characteristics or other potential modifiers, including PM2.5 chemical composition,” the authors concluded.
References
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More